Senescence and epigenetic dysregulation in cancer

International Journal of Biochemistry and Cell Biology

Volumn 34, Issue 11, 2002, Pages 1475-1490

  Neumeister, Peter ^a   Albanese, Chris ^a   Balent, Beate ^a   Greally, John ^a   Pestell, Richard G ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Acetylation; Aging; Cancer; Methylation; Senescence

Indexed keywords

MITOGENIC AGENT;

CANCER; CANCER GENETICS; CANCER INHIBITION; CARCINOGENESIS; CELL AGING; CELL CYCLE S PHASE; CELL DIVISION; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL STIMULATION; CELL STRUCTURE; CELL SURVIVAL; CELL TYPE; CPG ISLAND; DNA METHYLATION; GENE SILENCING; HUMAN; LONGEVITY; MAMMAL CELL; MOLECULAR MECHANICS; PROMOTER REGION; PROTEIN SYNTHESIS; REVIEW; SENESCENCE; TUMOR SUPPRESSOR GENE;

MAMMALIA;

EID: 0036830336     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-2725(02)00079-1     Document Type: Short Survey

References (134)

1. Hayflick L., Moorhead P.S. The serial cultivation of human diploid cell strains. Exp. Cell Res. 25:1961;585-621.
2. Hayflick L. The limited in vitro lifetime of human diploid strains. Exp. Cell Res. 37:1965;614-636.
3. Hayflick L. Mortality and immortality at the cellular level: a review. Biochemistry. 62:1997;1180-1190.
4. Sager R. Senescence as a mode of tumor suppression. Environ. Health Perspect. 93:1991;59-62.
5. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
6. Wolffe A.P., Matzke M.A. Epigenetics: regulation through repression. Science. 286:1999;481-486.
7. Wang E. Senescent human fibroblasts resist programmed cell death and failure to suppress bcl2 is involved. Cancer Res. 55:1995;2284-2292.
8. Campisi J. Replicative senescence: an old live's tale? Cell. 84:1996;497-500.
9. Bayreuther K.H., Rodemann H.P., Hommel R., Dittmann K., Albiez M., Francz P.I. Human skin fibroblasts in vitro differentiate along a terminal cell lineage. Proc. Natl. Acad. Sci. U.S.A. 85:1988;5112-5116.
10. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., Medrano E.E., Linsken M., Rubelj I., Pereira-Smith O.M., Peacocke M., Campisi J. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. U.S.A. 92:1995;9363-9367.
11. Schneider E.L., Mitsui Y. The relationship between in vitro cellular aging and in vivo human age. Proc. Natl. Acad. Sci. U.S.A. 73:1976;3584-3588.
12. Wright W.E., Pereira-Smith O.M., Shay J.W. Reversible cellular senescence: implications for immortalization of normal human diploid fibroblasts. Mol. Cell. Biol. 9:1989;3088-3092.
13. Wyllie A.H., Kerr J.F., Currie A.R. Cell death: the significance of apoptosis. Int. Rev. Cytol. 68:1980;251-306.
14. Bergers G., Hanahan D., Croussens L.M. Angiogenesis and apoptotic rates are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis. Int. J. Dev. Biol. 42:1998;995-1002.
15. Shibata M.A., Maroulakou I.G., Jorcyk C.L., Gold L.G., Ward J.M., Green J.E. p53-independent apoptosis during mammary tumor progression in C3 (1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from pre-neoplasia to carcinoma. Cancer Res. 56:1996;2998-3003.
16. Shay J.W., Wright E.W. When do telomeres matter? Science. 291:2001;839-840.
17. Sherr C.J., DePinho R.A. Cellular senescence: mitotic clock or culture shock? Cell. 102:2000;407-410.
18. Olovnikov A.M. A theory of marginotomy. J. Theor. Biol. 41:1973;181-190.
19. Reddel R.R. The role of senescence and immortalization in carcinogenesis. Carcinogenesis. 21:2000;477-884.
20. Stewart S.A., Weinberg R.A. Telomerase and human tumorigenesis. Semin. Cancer Biol. 10:2000;399-406.
21. Greider C.W. Telomere length regulation. Ann. Rev. Biochem. 65:1996;337-365.
22. Urquidi V., Tarin D., Goodison S. Role of telomerase in cell senescence and oncogenesis. Ann. Rev. Med. 51:2000;65-79.
23. Sandell L.L. Loss of a yeast telomere: arrest, recovery and chromosomal loss. Cell. 75:1993;729-739.
24. Lingner J., Cooper J.P., Cech T.R. Telomerase and DNA end replication: no longer a lagging strand problem? Science. 269:1995;1533-1534.
25. Harley C.B., Futcher A.B., Greider C.W. Telomeres shorten during aging of human fibroblasts. Nature. 345:1990;458-460.
26. Counter C.M., Avilion A.A., LeFeuvre C.E. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 11:1992;1921-1929.
27. Hastie N.D., Dempster M., Dunlop M.G. Telomere reduction in human colorectal carcinoma and with aging. Nature. 346:1990;866-868.
28. Meyerson M., Counter C.M., Eaton E.N., Ellisen L.W., Steiner P., Caddle S.D., Ziaugra L., Beijersbergen R.L., Davidoff M.J., Liu Q., Bacchetti S., Haber D.A., Weinberg R.A. hEST2, the putative human telomerase catalytic subunit gene, is upregulated in tumor cells and during immortalization. Cell. 90:1997;785-795.
29. Bodnar A.G., Ouelette M., Frolkis M., Holt S.E., Chiu C.P., Morin G.B., Harley C.B., Shay J.W., Lichtsteiner S., Wright W.E. Extension of lifespan by introduction of telomerase into normal human cells. Science. 279:1989;349-352.
30. Yang J., Chang E., Cherry A.M., Bangs C.D., Oei Y., Bodnar A., Bronstein A., Chiu C.P., Herron G.S. Human endothelial cell life extension by telomerase expression. J. Biol. Chem. 274:1999;26141-26148.
31. Shay J.W., Bacchetti S. A survey of telomerase activity in human cancer. Eur. J. Cancer. 33:1997;787-791.
32. Bryan T.M., Engelzou A., Gupta J., Bacchetti S., Reddel R.R. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J. 14:1995;4240-4248.
33. Karlseder J., Smogorzewsk A., de Lange T. Senescence induced by altered telomere state, not telomere loss. Science. 295:2002;2446-2449.
34. INK4a/INK4a-enforced mechanism that limits lifespan become immortal yet retain normal growth and differentiation characteristics. Mol. Cell. Biol. 20:2000;1436-1447.
35. INK4a/INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature. 396:1998;84-88.
36. Russo I., Silver A.R., Cuthbert A.P., Griffin D.K., Troo D.A., Newbold R.F. A telomere independent senescence mechanism is the sole barrier to Syrian hamster cell immortalization. Oncogene. 17:1998;3417-3426.
37. Wei S., Sedivy J.M. Expression of catalytically active telomerase does not prevent premature senescence caused by overexpression of oncogenic Ha-Ras in normal human fibroblasts. Cancer Res. 59:1999;1539-1543.
38. Wakimoto B.T. Beyond the nucleosome: epigenetic aspects of position-effect variegation in Drosophila. Cell. 93:1998;321-324.
39. Baur J.A., Zou Y., Shay J.W., Wright W.E. Telomere position effect in human cells. Science. 292:2001;2075-2077.
40. Won K.A., Xiong Y., Beach D., Gilman M.Z. Growth-regulated expression of D-type cyclin genes in human diploid fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 89:1992;9910-99914.
41. CIP1 in the mechanism of senescence and differentiation in human fibroblasts. Mol. Cell. Biol. 19:1999;2109-2117.
42. INK4a. Cell. 88:1997;593-602.
43. INK4a in replicative senescence of normal human fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 93:1996;13742-13747.
44. Zhu J., Woods D., McMahon M., Bishop J.M. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev. 12:1998;2997-3007.
45. INK4a is activated in response to constitutive MEK7MAPK mitogenic signaling. Genes Dev. 12:1998;3008-3019.
46. Ferbeyre G., de Stanchina E., Querido E., Baptiste N., Prives C., Lowe S.W. PML is induced by oncogenic Ras and promotes premature senescence. Genes Dev. 14:2000;2015-2027.
47. Pearson M., Carbone R., Sebastiani C., Cioce M., Fagiola M., Saito S., Higashimoto Y., Appella E., Minucci S., Pandolfi P.P., Pelicci P.G. PML regulates p53 acetylation and premature senescence by oncogenic Ras. Nature. 13:2000;207-210.
48. INK4a/INK4a expression during cellular senescence. Nature. 409:2001;1067-1070.
49. Xu H.J., Zhou Y., Ji W., Perng G.S., Kruzelock R., Kong C.T., Bast R.C., Mills G.B., Li J., Hu S.X. Re-expression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition. Oncogene. 15:1997;2589-2596.
50. KIP1/KIP1 in retinoblastoma protein mediated senescence. Mol. Cell. Biol. 21:2001;3616-3631.
51. Duncan B.K., Miller J.H. Mutagenic deamination of cytosine residues in DNA. Nature. 287:1980;560-561.
52. Lander E.S., Linton L.M.et al. Initial sequencing and analysis of the human genome. Nature. 409:2001;860-921.
53. Ponger L., Duret L., Mouchiroud D. Determinants of CpG islands: expression in early embryo and isochore structure. Genome Res. 11:2001;1854-1860.
54. Baylin S.B., Herman J.G., Graff J.R., Vertino P.M., Issa J.P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res. 72:1997;141-196.
55. Kass S.U., Landsberger N., Wolffe A.P. DANN methylation directs a time-dependent repression of transcription initiation. Curr. Biol. 7:1997;157-165.
56. Piko L., Hammons M.D., Taylor K.D. Amounts, synthesis, and some properties of intracisternal A particle-related RNA in early mouse embryos. Proc. Natl. Acad. Sci. U.S.A. 81:1984;488-492.
57. Roundtree M.R., Bachmann K.E., Hermann J.G., Baylin S.B. DNA methylation, chromatin inheritance and cancer. Oncogene. 20:2001;3156-3165.
58. Yoder J.A., Yen R.C., Vertino P.M., Bestor T.H., Baylin S.B. New 5′-regions of the murine and human genes for DNA (cytosine-5)-methyltransferase. J. Biol. Chem. 271:1996;31092-31097.
59. Bird A. DNA methylation de novo. Science. 286:1999;2287-2288.
60. Rountree M.R., Bachman K.E., Baylin S.B. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat. Genet. 25:2000;269-277.
61. Bachman K.E., Rountree M.R., Baylin S.B. Dnmt3a and Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterochromatin. J. Biol. Chem. 276:2001;32282-32287.
62. Hasse A., Schulz W.A. Enhancement of reporter gene de novo methylation by DNA fragments from the α-fetoprotein control region. J. Biol. Chem. 269:1994;1821-1826.
63. Yates P.A., Burman R.W., Mummaneni P., Krussel S., Turker M.S. Tandem B1 elements located in a mouse methylation center provide a target for de novo DNA methylation. J. Biol. Chem. 274:1999;36357-36361.
64. Arnaud P., Goubely C., Pelissier T., Deragon J.M. SINE retroposons can be used in vivo as nucleation centers for de novo methylation. Mol. Cell. Biol. 20:2000;3434-3441.
65. Tamaru H., Selker E.U. A histone H3 methyltransferase controls DNA methylation in Neurospora crassa. Nature. 414:2001;277-283.
66. Peters A.H., O'Carroll D., Schertan H., Mechtler K., Sauer S., Schofer C., Weipoltshammer K., Pagani M., Lachner M., Kohlmaier A., Opravil S., Doyle M., Sibilia M., Jenuwein T. Loss of the suv39h histone methyltransferases impairs Mammalian heterochromatin and genome stability. Cell. 107:2001;323-337.
67. Bestor T.H. The DNA methyltransferases of mammals. Hum. Mol. Genet. 9:2000;2395-2402.
68. Hendrich B., Bird A. Mammalian methyltransferases and methyl-CpG binding domains: proteins involved in DNA methylation. Curr. Top. Microbiol. Immunol. 249:2000;55-74.
69. Ng H.H., Bird A. DNA methylation and chromatin modification. Curr. Opin. Genet. Dev. 9:1999;158-163.
70. Yoder J.A., Walsh C.P., Bestor T.H. Cytosine methylation and the ecology of intragenomic parasites. Trends Genet. 13:1997;335-340.
71. Grunau C., Clark S.J., Rosenthal A. Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucleic Acids Res. 29:2001;E65-65.
72. Bird A., Taggart M., Nicholls R.D., Higgs D.R. A fraction of the mouse genome that is derived from islands of non-methylated, CpG-rich DNA. Cell. 40:1985;91-99.
73. Deng G.A., Chen A., Pong E., Kim Y.S. Methylation in hMLH1 promoter interferes with its binding to transcription factor CBF and inhibits gene expression. Oncogene. 20:2001;7120-7127.
74. Cui H., Niemitz E.L., Ravenel J.D., Onyango P., Brandenburg S.A., Lobanenkov V.V., Feinberg A.P. Loss of imprinting of insulin-like growth factor II in Wilm's tumor commonly involves altered methylation but not mutations of CTCF or its binding site. Cancer Res. 61:2001;4947-4950.
75. Nakagawa H., Chadwick R.B., Peltomaki P., Plass C., Nakamura Y., De La Chapelle A. Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. Proc. Natl. Acad. Sci. U.S.A. 98:2001;591-596.
76. Chen R.Z., Pettersson U., Beard C., Jackson-Grusby L., Jaenisch R. DNA hypomethylation leads to elevated mutation rates. Nature. 395:1998;89-93.
77. Tuck-Muller C.M., Narayan A., Tsien F., Smeets D.F., Sawyer J., Fiala E.S., Sohn O.S., Ehrlich M. DNA hypomethylation and unusual chromosome instability in cell lines from ICF syndrome patients. Cytogenet. Cell Genet. 89:2000;121-128.
78. Xu G.L., Bestor T.H., Bourchis D., Hsieh C.L., Tommerup N., Bugge M., Hulten M., Qu X., Russo J.J., Viegas-Pequignot E. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature. 402:1999;187-191.
79. Lee P.J., Washer L.L., Law D.J., Boland C.R., Horon I.L., Feinberg A.P. Limited upregulation of DNA methyltransferase in human colon cancer reflecting increased cell proliferation. Proc. Natl. Acad. Sci. U.S.A. 93:1996;10366-10370.
80. Robertson K.D., Uzvolgyi E., Liang G., Talmadge C., Sumegi J., Gonzales F.A., Jones P.A. The human DNA methyltransferases (DNMTs) 1, 3a and 3b coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res. 27:1999;2291-2298.
81. Belinsky S.A., Belinsky S.A., Nikula K.J., Baylin S.B., Issa J.P. Increased cytosine DNA methyltransferase activity is target cell-specific and an early event in lung cancer. Proc. Natl. Acad. Sci. U.S.A. 93:1996;4045-4050.
82. Robertson K.D., Uzvolgyi E., Liang G., Talmadge C., Sumegi J., Gonzales F.A., Jones P.A. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res. 27:1999;2291-2298.
83. Wu J., Issa J.P., Herman J., Bassett D.E. Jr., Nelkin B.D., Baylin S.B. Expression of an exogenous eukaryotic DNA methyltransferase gene induces transformation of NIH3T3 cells. Proc. Natl. Acad. Sci. U.S.A. 90:1993;8891-8895.
84. Vertino P.M., Yen R.W., Gao J., Baylin S.B. De novo methylation of CpG island sequences in human fibroblasts overexpressing DNA (cytosine-5)-methyltransferase. Mol. Cell. Biol. 16:1996;4555-4565.
85. MacLeod A.R., Szyf M. Expression of antisense to DNA methyltransferase mRNA induces DNA demethylation and inhibits tumorigenesis. J. Biol. Chem. 270:1995;8037-8043.
86. Issa J.P. Aging, DNA methylation and cancer. Crit. Rev. Oncol. Hematol. 32:1999;31-43.
87. Laird P.W., Jaenisch R. The role of DNA methylation in cancer genetic and epigenetics. Annu. Rev. Genet. 30:1996;441-464.
88. Rhee I., Bachman K.E., Park B.H., Jair K.W., Chiu Yen R.W., Schuebel K.E., Cui H., Feinberg A.P., Lengauer C., Kinzler K.W., Baylin S.B., Vogelstein B. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature. 416:2002;552-556.
89. Di Croce L., Raker V.A., Corsaro M., Fazi F., Fanelli M., Faretta M., Fuks F., Lo Coco F., Kouzarides T., Neri C., Minucci S., Pelicci P.G. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science. 295:2002;1079-1082.
90. Issa J.P., Ottaviano Y.L., Celano P., Hamilton S.R., Davidson N.E., Baylin S.B. Methylation of the estrogen receptor CpG island links aging and neoplasia in human colon. Nat. Genet. 7:1994;536-540S.
91. Ottaviano Y.L., Issa J.P., Parl F.F., Smith H.S., Baylin S.B., Davidson N.E. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 54:1994;2552-2555.
92. Lapidus R.G., Ferguson A.T., Ottaviano Y.L., Parl F.F., Smith H.S., Weitzman S., Baylin S.B., Issa J.P.J., Davidson N.E. Methylation of estrogen and progesterone receptor gene of CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin. Cancer Res. 2:1996;805-810.
93. Issa J.P.J., Vertino P.M., Boehm C.D., Newsham I.F., Baylin S.B. Switch from mono- to bi-allelic human IGF2 promoter methylation during aging and carcinogenesis. Proc. Natl. Acad. Sci. U.S.A. 93:1996;11757-11762.
94. Siegfried Z., Eden S., Mendelsohn M., Feng X., Tsuberi B.Z., Cedar H. DNA methylation represses transcription in vivo. Nat. Genet. 22:1999;203-206.
95. Razin A., Shemer R. Epigenetic control of gene expression. Results Probl. Cell. Differ. 25:1999;189-204; Baylin B., Herman J.G. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 16:2000;168-174.
96. Razin A., Shemer R. Epigenetic control of gene expression. Results Probl. Cell. Differ. 25:1999;189-204; Baylin B., Herman J.G. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 16:2000;168-174.
97. Szyf M. The role of DNA methyltransferase 1 in growth control. Front. Biosci. 6:2001;599-609.
98. Ng H.H., Zhang Y., Hendrich B., Johnson C.A., Turner B.M., Erdjument-Bromage H., Tempst P., Reinberg D., Bird A. MBD2 is a transcriptional repressor belonging to the MeCP1-histone deacetylase complex. Nat. Genet. 23:1999;58-61.
99. Wade P.A., Gegonne A., Jones P.L., Ballestar E., Aubry F., Wolffe A.P. Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat. Genet. 23:1999;62-66.
100. Bhattacharya S.K., Ramchandani S., Cervoni N., Szyf M. A mammalian protein with specific demethylase activity for mCpG DNA. Nature. 39:1999;7579-7583.
101. Ramchandani S., Bhattacharya S.K., Cervoni N., Szyf M. DNA methylation is a reversible biological signal. Proc. Natl. Acad. Sci. U.S.A. 96:1999;6107-6112.
102. Szyf M., Knox D.J., Milutinovic S., Slack A.D., Araujo F.D. How does DNA methyltransferase cause oncogenic transformation? Ann. N. Y. Acad. Sci. 910:2000;156-174. (Discussion, pp. 175-177).
103. MacLeod A.R., Rouleau J., Szyf M. Regulation of DNA methylation by the Ras signaling pathway. J. Biol. Chem. 270:1995;11327-11337.
104. Rouleau J., MacLeod A.R., Szyf M. Regulation of the DNA methyltransferase by the Ras-AP-1 signaling pathway. J. Biol. Chem. 270:1995;1595-1601.
105. Araujo F.D., Knox J.D., Szyf M., Price G.B., Zannis-Hadjopoulos M. Concurrent replication and methylation at mammalian origins of replication. Mol. Cell. Biol. 18:1998;3475-3482.
106. 1 to S phase transition in normal and tumor cells. Nucleic Acids Res. 28:2000;2108-2113.
107. Ramchandani S., MacLeod A.R., Pinard M., von Hofe E., Szyf M. Inhibition of tumorigenesis by a cytosine-DNA, methyltransferase, antisense oligodeoxy nucleotide. Proc. Natl. Acad. Sci. U.S.A. 94:1997;684-689.
108. Bender C.M., Pao M.M., Jones P.A. Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res. 58:1998;95-101.
109. Knox J.D., Araujo F.D., Bigey P., Slack A.D., Price G.B., Zannis-Hadjopoulos M., Szyf M. Inhibition of DNA methyltransferase inhibits DNA replication. J. Biol. Chem. 275:2000;17986-17990.
110. CIP1(WAF1/CIP1/sdi1). J. Biol. Chem. 275:2000;6353-6359.
111. Robertson K.D., Ait-Si-Ali S., Yokochi T., Wade P.A., Jones P.L., Wolffe A.P. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat. Genet. 25:2000;338-342.
112. Fuks F., Burgers W.A., Brehm A., Hughes-Davies L., Kouzarides T. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat. Genet. 24:2000;88-91.
113. Rountree M.R., Bachman K.E., Baylin S.B. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat. Genet. 25:2000;269-277.
114. CIP1/WAF1/CIP1 gene promoter through the Sp1 sites. Ann. N.Y. Acad. Sci. 886:1999;195-199; Bird A. The essentials of DNA methylation. Cell. 70:1992;5-8.
115. CIP1/WAF1/CIP1 gene promoter through the Sp1 sites. Ann. N.Y. Acad. Sci. 886:1999;195-199; Bird A. The essentials of DNA methylation. Cell. 70:1992;5-8.
116. Wharton W., Savell J., Cress W.D., Seto E., Pledger W.J. Inhibition of mitogenesis in BALB/c-3t3 cells by trichostatin A: multiple alterations in the induction and activation of cyclin/cdk complexes. J. Biol. Chem. 275:2000;33981-33987.
117. Palmisano W.A., Divine K.K., Saccomanno G., Gilliland F.D., Baylin S.B., Herman J.G., Belinsky S.A. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 60:2000;5954-5958.
118. De Marzo A.M., Marchi V.L., Yang E.S., Veeraswamy R., Lin X., Nelson W.G. Abnormal regulation of DNA methyltransferase expression during colorectal carcinogenesis. Cancer Res. 59:1999;3855-3860.
119. Nass S.J., Ferguson A.T., El-Ashry D., Nelson W.G., Davidson N.E. Expression of DNA methyltransferase (DMT) and the cell cycle in human breast cancer cells. Oncogene. 18:1999;7453-7461.
120. Guarente L. Sir2 links chromatin silencing, metabolism and aging. Genes Dev. 14:2000;1021-1026.
121. Kaeberlein M.M., Vey Mc., Guarente L. The SIR2/SIR3/SIR4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev. 13:1999;2570-2580.
122. Tsukamoto Y., Kato J., Ikeda H. Silencing factors participate in DNA repair and recombination in Saccharomyces cerevisiae. Nature. 388:1997;900-903.
123. Martin S.G., Laroche T., Suka N., Grunstein M., Gasser S.M. Re-localization of telomeric Ku and SIR proteins in response to DNA double strand breaks in yeast. Cell. 97:1999;631-633.
124. Mills K.D., Sinclair D.A., Guarente L. MEC-1 dependent redistribution of the Sir3 silencing protein from telomeres to DNA double strand breaks. Cell. 97:1999;609-620.
125. Gottlieb S., Esposito R.E. A new role for yeast transcriptional silencer gene, SIR2, in regulation of recombination in ribosomal DNA. Cell. 56:1989;771-776.
126. Sinclair D.A., Guarente L. Extrachromosomal rDNA circles: a cause of aging in yeast. Cell. 91:1997;1-20.
127. Imai S., Armstrong C., Guarente L. Silencing and aging protein Sir2 is an NAD-dependent histone deacetylase. Nature. 403:2000;795-800.
128. Luo J., Nikolaev A.Y., Imai S., Chen D., Su F., Shiloh A., Guarente L., Gu W. Negative control of p53 by Sir2α promotes cell survival under stress. Cell. 107:2001;137-148.
129. Vaziri H., Dessain S.K., Eaton E.N., Imai S., Frey R.A., Pandita T.K., Guarente L., Weinberg R.A. hSIR2SIRT1 functions as an NAD-dependent p53 deacetylase. Cell. 107:2001;149-159.
130. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature. 408:2000;307-310.
131. Hollstein M., Rice K., Greenblatt M.S., Soussi T., Fuchs R., Sorlie T., Hovig E., Smith-Sorensen B., Montesano R., Harris C.C. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 22:1994;3551-3555.
132. Wang C., Fu M., Mani S., Wadler S., Senderowicz A.M., Pestell R. Histone acetylation and the cell cycle in cancer. Front. Biosci. 6:2001;610-629.
133. Wang C., Fu M., Angeletti R.H., Siconolfi-Baez L., Reutens A.T., Albanese C., Lisanti M.P., Katzenellenbogen B.S., Kato S., Hopp T., Fuqua S.A., Lopez G.N., Kushner P.J., Pestell R.G. Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity. J. Biol. Chem. 276:2001;18375-18383.
134. Fu M., Wang C., Reutens A.T., Wang J., Angeletti R.H., Siconolfi-Baez L., Ogryzko V., Avantaggiati M.L., Pestell R.G. p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J. Biol. Chem. 275:2000;20853-20860.